Humacyte(HUMA) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Humacyte Third Quarter 2024 Financial Results and Business Update - FDA review of acellular tissue engineered vessel (ATEV™) BLA for the Treatment of Vascular Trauma is ongoing - - Results from the V007 Phase 3 clinical trial of the ATEV in arteriovenous (AV) access for hemodialysis patients presented at American Society of Nephrology's Kidney Week 2024 - - Long-term results from the humanitarian program where the ATEV was used to treat vascular injuries suffered during the Ukraine conflict wer ...